Article
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.
The Annals of pharmacotherapy - 1 Feb 2011
Li-Wan-Po Alain, Farndon Peter A, Kobayashi Susumu, Mitsudomi Tetsuya, Potter Vanessa A
Abstract excerpt
OBJECTIVE: To illustrate the increasing importance of pharmacogenetics in drug development and clinical practice through a critical analysis of the validation and licensing of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as a treatment for non-small cell lung c...
Topics
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials, Phase III as Topic
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Prospective Studies
- Quinazolines
- Retrospective Studies
- Risk Assessment
- Technology Transfer